Private equity funds that own German drugmaker Stada Arzneimittel AG have decided to postpone its planned initial public ...

Verisure’s majority owner Hellman & Friedman has lined up more banks for a potential initial public offering of the security firm, as it steps up preparations for what could be one of Europe’s largest ...

--Stada's listing plans are still being discussed and subject to change, according to Bloomberg. JPMorgan Chase, Morgan Stanley, Deutsche Bank, and Goldman Sachs are leading the Stada IPO as global ...

Q4 2024. Management View. CEO Adam Levy highlighted that 2024 was a pivotal year for NEXGEL, achieving over 100% revenue growth for the third ...

Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior yearFull year ...

Private equity firm Hellman & Friedman has selected banks to lead the initial public offering of security group Verisure, ...

German pharmaceutical company Stada Arzneimittel has delayed its IPO to the third quarter, while in the same country ...

Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112 ...

FRANKFURT (Reuters) -French banking group Credit Mutuel Alliance Federale is buying German lender Oldenburgische Landesbank ...

Hellman & Friedman has selected Goldman Sachs and Morgan Stanley to lead the IPO of security firm Verisure, potentially ...

Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...